<?xml version="1.0" encoding="UTF-8"?>
<ref id="cas14841-bib-0019">
 <label>19</label>
 <mixed-citation publication-type="journal" id="cas14841-cit-0019">
  <string-name>
   <surname>Stintzing</surname>
   <given-names>S</given-names>
  </string-name>, 
  <string-name>
   <surname>Wirapati</surname>
   <given-names>P</given-names>
  </string-name>, 
  <string-name>
   <surname>Lenz</surname>
   <given-names>HJ</given-names>
  </string-name>, et al. 
  <article-title>Consensus molecular subgroups (CMS) of colorectal cancer (CRC) and 1st‐line efficacy of FOLFIRI plus cetuximab or bevacizumab in the FIRE3 (AIO KRK‐0306) trial</article-title>. 
  <source xml:lang="en">Ann Oncol</source>. 
  <year>2019</year>;
  <volume>30</volume>(
  <issue>11</issue>):
  <fpage>1796</fpage>‐
  <lpage>1803</lpage>.
  <pub-id pub-id-type="pmid">31868905</pub-id>
 </mixed-citation>
</ref>
